Tocotrienol combination therapy results in synergistic anticancer response

Frontiers in Bioscience

Volumn 16, Issue 7, 2011, Pages 3183-3195

  Sylvester, Paul W ^a   Wali, Vikram B ^a   Bachawal, Sunitha V ^a   Shirode, Amit B ^a   Ayoub, Nehad M ^a   Akl, Mohamed R ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Akt; Apoptosis; Combination chemotherapy; Cyclooxygenase 2 inhibitors; Mammary cancer; NF B; PI3K; Receptor tyrosine kinase inhibitors; Review; Statins; Tocotrienols; Vitamin E

Indexed keywords

ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; NEOPLASM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TOCOTRIENOLS;

EID: 79959562482     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3905     Document Type: Article

References (81)

1. Cancer Facts and Figures. American Cancer Society (2009).
2. Marshall E: Epidemiology. Search for a killer: focus shifts from fat to hormones. Science 259, 618-621 (1993).
3. Vogel VG, Yeomans A, Higginbotham E: Clinical management of women at increased risk for breast cancer. Breast Cancer Res Treat 28, 195-210 (1993). (Pubitemid 24056090)
4. Medina D: Mammary tumorigenesis in chemical carcinogen-treated mice. I. Incidence in BALB-c and C57BL mice. J Natl Cancer Inst 53, 213-221 (1974).
5. Nagasawa H, Yanai R, Taniguchi H: Importance of mammary gland DNA synthesis on carcinogen-induced mammary tumorigenesis in rats. Cancer Res 36, 2223-2226 (1976).
6. Russo IH, Russo J: Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethylbenz (a)anthracene. J Natl Cancer Inst 61, 1439-1449 (1978). (Pubitemid 9070679)
7. Sylvester PW, Aylsworth CF, Van Vugt DA, Meites J: Effects of alterations in early hormonal environment on development and hormone dependency of carcinogeninduced mammary tumors in rats. Cancer Res 43, 5342-5346 (1983). (Pubitemid 14230149)
8. Sylvester PW, Ip C, Ip MM: Effects of high dietary fat on the growth and development of ovarian-independent carcinogen-induced mammary tumors in rats. Cancer Res 46, 763-769 (1986). (Pubitemid 16145435)
9. Guzman RC, Osborn RC, Swanson SM, Sakthivel R, Hwang SI, Miyamoto S, Nandi S: Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice. Cancer Res 52, 5732-5737 (1992).
10. Imagawa W, Bandyopadhyay GK, Garcia M, Matsuzawa A, Nandi S: Pregnancy-dependent to ovarianindependent progression in mammary tumors delineated in primary culture: changes in signal transduction, growth factor regulation, and matrix interaction. Cancer Res 52, 6531-6538 (1992).
11. Swanson SM, Guzman RC, Collins G, Tafoya P, Thordarson G, Talamantes F, Nandi S: Refractoriness to mammary carcinogenesis in the parous mouse is reversible by hormonal stimulation induced by pituitary isografts. Cancer Lett 90, 171-181 (1995).
12. Swanson SM, Guzman RC, Tsukamoto T, Huang TT, Dougherty CD, Nandi S: N-Ethyl-N-nitrosourea induces mammary cancers in the pituitary-isografted mouse which are histologically and genotypically distinct from those induced by N-methyl-N-nitrosourea. Cancer Lett 102, 159-165 (1996).
13. Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 92, 3650-3657 (1995).
14. Goh SH, Hew NF, Norhanom AW, Yadav M: Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 57, 529-531 (1994). (Pubitemid 24173098)
15. Rogers AE, Lee SY: Chemically-induced mammary gland tumors in rats: modulation by dietary fat. Prog Clin Biol Res 222, 255-282 (1986).
16. Sundram K, Khor HT, Ong AS: Effect of dietary palm oil and its fractions on rat plasma and high density lipoprotein lipids. Lipids 25, 187-193 (1990). (Pubitemid 20135049)
17. Sylvester PW, Russell M, Ip MM, Ip C: Comparative effects of different animal and vegetable fats fed before and during carcinogen administration on mammary tumorigenesis, sexual maturation, and endocrine function in rats. Cancer Res 46, 757-762 (1986). (Pubitemid 16145434)
18. Nakayama M, Ju HR, Sugano M, Hirose N, Ueki T, Doi F, Eynard AR: Effect of dietary fat and cholesterol on dimethylbenz (a)-anthracene-induced mammary tumorigenesis in Sprague-Dawley rats. Anticancer Res 13, 691-698 (1993). (Pubitemid 23216968)
19. Cottrell RC: Introduction: nutritional aspects of palm oil. Am J Clin Nutr 53, 989S-1009S (1991).
20. Bachawal SV, Wali VB, Sylvester PW: Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 30, 429-437 (2010).
21. Bachawal SV, Wali VB, Sylvester PW: Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10, 84 (2010).
22. Shirode AB, Sylvester PW: Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 64, 327-332 (2010).
23. Wali VB, Sylvester PW: Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 42, 1113-1123 (2007). (Pubitemid 350303593)
24. Wali VB, Bachawal SV, Sylvester PW: Suppression in Mevalonate Synthesis Mediates Antitumor Effects of Combined Statin and gamma-Tocotrienol Treatment. Lipids 44, 925-934 (2009).
25. Wali VB, Bachawal SV, Sylvester PW: Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med 234, 639-650 (2009).
26. Elson CE: Tropical oils: nutritional and scientific issues. Crit Rev Food Sci Nutr 31, 79-102 (1992).
27. McIntyre BS, Briski KP, Gapor A, Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224, 292-301 (2000). (Pubitemid 30643508)
28. Sylvester PW, Theriault A: Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res 1, 121-136 (2003).
29. Sylvester PW, Shah SJ: Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 10, 699-709 (2005).
30. McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35, 171-180 (2000). (Pubitemid 30183648)
31. Packer L: Protective role of vitamin E in biological systems. Am J Clin Nutr 53, 1050S-1055S (1991). (Pubitemid 21898873)
32. Kimmick GG, Bell RA, Bostick RM: Vitamin E and breast cancer: a review. Nutr Cancer 27, 109-117 (1997). (Pubitemid 27089683)
33. Sylvester PW: Antiproliferative and apoptotic effects of tocotrienols on normal and neoplastic mammary epithelial cells. In: Tocotrienols: Vitamin E Beyond Tocopherols, Eds: RR Watson and VR Preedy. CRC Press, Boca Raton, Florida (2009).
34. Sylvester PW: Vitamin E and apoptosis. In: Vitamins and Hormones , Volume 76. Eds: G Litwack. Academic Press, San Diego, California (2007).
35. Sundram K, Khor HT, Ong AS, Pathmanathan R: Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz (a)anthracene. Cancer Res 49, 1447-1451 (1989). (Pubitemid 19088680)
36. Nesaretnam K, Khor, H.T., Ganeson, J., Chong, Y.H., Sundram, K., and Gapor, A.: The effects of vitamin E tocotrienols from palm oil on chemically induced mammary carcingenesis in female rats. Nutr Res 12, 879-892 (1992).
37. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK: Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30, 1139-1143 (1995).
38. Nesaretnam K, Stephen R, Dils R, Darbre P: Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 33, 461-469 (1998). (Pubitemid 28261949)
39. Nesaretnam K, Dorasamy S, Darbre PD: Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr 51, Suppl: S95-103 (2000). (Pubitemid 32007600)
40. Gould MN, Haag JD, Kennan WS, Tanner MA, Elson CE: A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am J Clin Nutr 53, 1068S-1070S (1991). (Pubitemid 21898877)
41. Sylvester PW: Vitamin E-induced apoptosis in mouse mammary tumors. In: New Cell Apoptosis Research, Eds: RG Valentino, Nova Science Publisher, Inc. New York, New York: (2007).
42. Nesaretnam K: Multitargeted therapy of cancer by tocotrienols. Cancer Lett 269, 388-395 (2008).
43. Sylvester PW, McIntyre BS, Gapor A, Briski KP: Vitamin E inhibition of normal mammary epithelial cell growth is associated with a reduction in protein kinase C (alpha) activation. Cell Prolif 34, 347-357 (2001). (Pubitemid 34015673)
44. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006). (Pubitemid 43199589)
45. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61, Suppl 2, 1-13 (2001). (Pubitemid 33033419)
46. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137 (2001). (Pubitemid 33674041)
47. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10, 6487-6501 (2004). (Pubitemid 39346544)
48. Sylvester PW, Nachnani A, Shah S, Briski KP: Role of GTP-binding proteins in reversing the antiproliferative effects of tocotrienols in preneoplastic mammary epithelial cells. Asia Pac J Clin Nutr 11, Suppl 7, S452-459 (2002).
49. Shah SJ, Sylvester PW: Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med 230, 235-241 (2005). (Pubitemid 40478247)
50. Samant GV, Sylvester PW: gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 39, 563-574 (2006). (Pubitemid 44760206)
51. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H: Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med 232, 523-531 (2007). (Pubitemid 46524474)
52. Baldwin AS, Jr.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14, 649-683 (1996). (Pubitemid 26130197)
53. Biswas DK, Cruz A, Pettit N, Mutter GL, Pardee AB: A therapeutic target for hormone-independent estrogen receptor-positive breast cancers. Mol Med 7, 59-67 (2001). (Pubitemid 33702000)
54. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB: The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98, 10386-10391 (2001). (Pubitemid 32803029)
55. Sliva D, Rizzo MT, English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDAMB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 277, 3150-3157 (2002). (Pubitemid 34953176)
56. Khwaja A: Akt is more than just a Bad kinase. Nature 401, 33-34 (1999).
57. Schlatter R, Schmich K, Avalos Vizcarra I, Scheurich P, Sauter T, Borner C, Ederer M, Merfort I, Sawodny O: ON/OFF and beyond-a boolean model of apoptosis. PLoS Comput Biol 5: e1000595 (2009).
58. Fulda S, Gorman AM, Hori O, Samali A: Cellular stress responses: cell survival and cell death. Int J Cell Biol 2010, 214074 (2010).
59. Wang G, Yang ZQ, Zhang K: Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2, 65-74 (2010).
60. Samali A, Fitzgerald U, Deegan S, Gupta S: Methods for monitoring endoplasmic reticulum stress and the unfolded protein response. Int J Cell Biol 2010, 830307 (2010)
61. Shah S, Gapor A, Sylvester PW: Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 45, 236-246 (2003). (Pubitemid 37022798)
62. Shah S, Sylvester PW: Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med 229, 745-755 (2004). (Pubitemid 39166478)
63. Sylvester PW, Shah S: Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Asia Pac J Clin Nutr 14, 366-373 (2005). (Pubitemid 43219093)
64. Shah SJ, Sylvester PW: Tocotrienol-induced cytotoxicity is unrelated to mitochondrial stress apoptotic signaling in neoplastic mammary epithelial cells. Biochem Cell Biol 83, 86-95 (2005). (Pubitemid 40637970)
65. Takahashi K, Loo G: Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. Biochem Pharmacol 67, 315-324 (2004). (Pubitemid 38112762)
66. Wali VB, Bachawal SV, Sylvester PW: Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells. Apoptosis 14, 1366-1377 (2009).
67. Park SK, Sanders BG, Kline K: Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res Treat 124, 361-375 (2010).
68. Guthrie N, Gapor A, Chambers AF, Carroll KK: Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127, 544S-548S (1997). (Pubitemid 27120013)
69. Hsieh TC, Wu JM: Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptorpositive MCF-7 breast cancer cells. Int J Oncol 33, 851-859 (2008).
70. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641 (2004). (Pubitemid 39451828)
71. Seeger H, Wallwiener D, Mueck AO: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111, 47-48 (2003). (Pubitemid 36336817)
72. Shibata MA, Ito Y, Morimoto J, Otsuki Y: Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25, 1887-1898 (2004). (Pubitemid 39405908)
73. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC: Breast cancer growth prevention by statins. Cancer Res 66, 8707-8714 (2006). (Pubitemid 44449187)
74. Habenicht AJ, Glomset JA, Ross R: Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by plateletderived growth factor. J Biol Chem 255, 5134-5140 (1980). (Pubitemid 10015833)
75. Fairbanks KP, Witte LD, Goodman DS: Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 259, 1546-1551 (1984). (Pubitemid 14104207)
76. Kaneko I, Hazama-Shimada Y, Endo A: Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem 87, 313-321 (1978). (Pubitemid 8355173)
77. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA: The dual role of mevalonate in the cell cycle. J Biol Chem 258, 378-385 (1983). (Pubitemid 13165761)
78. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK: Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 76, 1748-1754 (1985). (Pubitemid 16196041)
79. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346, 539-540 (2002).
80. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2, 483-491 (1996).
81. Britten CD: Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3, 1335-1342 (2004). (Pubitemid 39440177)